<p>PainReform Ltd. 宣布完成了对 LayerBio 专有的无滴、持续释放眼用药物递送平台的研发评估。结果确认该平台的持续释放聚合物基质能够结合多种药物实体。此发现支持该平台在长期内改善药理效率的潜力，并通过减少或消除对药用眼药水的需求，简化白内障患者的术后护理。该结果由公司宣布，尚未说明是否已在未来活动中展示或计划展示。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。PainReform Ltd. 于 2025 年 12 月 10 日通过 GlobeNewswire 发布了用于生成本新闻简报的原始内容（参考 ID：GNW9600032-en），并对此信息的内容承担全部责任。© 版权 2025 - 公共技术公司（PUBT）</p>

PRFX

<p>PainReform Ltd. 已完成对 LayerBio 持续释放眼用药物递送平台的研发评估。该平台可以结合多种药物，可能提高药理效率，并通过减少或消除对药物眼药水的需求，从而简化白内障患者的术后护理</p>

<p>PainReform Ltd. has announced the completion of a research and development assessment of LayerBio’s proprietary drop-less, sustained-release ocular drug-delivery platform. The results confirm that the platform’s sustained-release polymer matrix can incorporate a variety of drug entities. This finding supports the platform’s long-term potential to improve pharmacological efficiency and simplify postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops. The results were announced by the company and have not been specified as already presented or scheduled to be presented at a future event. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600032-en) on December 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>PainReform Ltd. 宣布完成了对 LayerBio 专有的无滴、持续释放眼用药物递送平台的研发评估。结果确认该平台的持续释放聚合物基质能够结合多种药物实体。此发现支持该平台在长期内改善药理效率的潜力，并通过减少或消除对药用眼药水的需求，简化白内障患者的术后护理。该结果由公司宣布，尚未说明是否已在未来活动中展示或计划展示。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。PainReform Ltd. 于 2025 年 12 月 10 日通过 GlobeNewswire 发布了用于生成本新闻简报的原始内容（参考 ID：GNW9600032-en），并对此信息的内容承担全部责任。© 版权 2025 - 公共技术公司（PUBT）</p>
</div>

PainReform 确认 LayerBio 的眼科平台能够以持续释放的形式递送多种药物